Bio-Rad Laboratories is moving its Droplet Digital PCR platform and liquid biopsy assays further into the commercial clinical space with recent regulatory approvals and submissions . Bio-Rad recently provided glimpses into its IVD strategies for the platform in a number of forums, illustrating the challenges and opportunities it sees going forward as it potentially introduces the technology to new users and expands its customer base.

Source : Genomeweb

>> Read full article